Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeNo recent work listed

Congwei Jia

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1438-9788; OpenAlex author ID A5060764634. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2013: 2 papers · 2014: 2 papers · 2015: 2 papers · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: none · 2020: 1 paper

Papers 10

  1. Development of a four-gene prognostic model for pancreatic cancer based on transcriptome dysregulation. Co-author DOI 10.18632/aging.102844↗
  2. Loss of ARID1A Expression Correlates With Tumor Differentiation and Tumor Progression Stage in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1177/1533034618754475↗
  3. Establishment of a non‑coding RNAomics screening platform for the regulation of KRAS in pancreatic cancer by RNA sequencing. Co-author DOI 10.3892/ijo.2018.4560↗
  4. Effects of miR-125a-5p on Cell Proliferation,Apoptosis and Cell Cycle of Pancreatic Cancer Cells. Co-author DOI 10.3881/j.issn.1000-503x.2016.04.009↗
  5. MiRNA-615-5p functions as a tumor suppressor in pancreatic ductal adenocarcinoma by targeting AKT2. Co-author DOI 10.1371/journal.pone.0119783↗
  6. Correction: MiRNA-615-5p Functions as a Tumor Suppressor in Pancreatic Ductal Adenocarcinoma by Targeting AKT2. Co-author DOI 10.1371/journal.pone.0128257↗
  7. Retinoic acid inhibits pancreatic cancer cell migration and EMT through the downregulation of IL-6 in cancer associated fibroblast cells. Co-author DOI 10.1016/j.canlet.2013.12.006↗
  8. High expression of interleukin-22 and its receptor predicts poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1245/s10434-013-3322-x↗
  9. [Target prediction and verification of miR-27a in pancreatic cancer]. Co-author DOI 10.3760/cma.j.issn.0529-5807.2013.06.008↗
  10. [MiR-150-5p inhibits the proliferation and promoted apoptosis of pancreatic cancer cells]. Co-author DOI 10.3760/cma.j.issn.0529-5807.2013.07.007↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shuangni Yu · 6 shared papers, 2013–2020 · strength 0.47
  2. Jie Chen · 4 shared papers, 2014–2020 · strength 0.35
  3. Cuiping Wang · 4 shared papers, 2015–2018 · strength 0.30
  4. Tingting Zhang · 5 shared papers, 2013–2016 · strength 0.28
  5. Yang Sun · 5 shared papers, 2013–2015 · strength 0.24
  6. Jie Chen · 4 shared papers, 2013–2015 · strength 0.20
  7. Xianglan Jin · 3 shared papers, 2013–2015 · strength 0.16
  8. Jie Yan · 1 shared paper, 2020 · strength 0.13
  9. Li Zhang · 1 shared paper, 2018 · strength 0.10
  10. Li Zhang · 1 shared paper, 2018 · strength 0.09
  11. Yang Sun · 1 shared paper, 2016 · strength 0.08
  12. Jie Chen · 1 shared paper, 2016 · strength 0.08
  13. Yingxin Wei · 1 shared paper, 2014 · strength 0.04
  14. Quan Liao · 1 shared paper, 2014 · strength 0.04
  15. Jianguo Zhao · 1 shared paper, 2014 · strength 0.04
  16. Zhang Wen · 1 shared paper, 2014 · strength 0.04
  17. Yupei Zhao · 1 shared paper, 2014 · strength 0.04
  18. Lei You · 1 shared paper, 2014 · strength 0.04
  19. Hui Zhang · 1 shared paper, 2014 · strength 0.04
  20. Yumei Gu · 1 shared paper, 2014 · strength 0.04
  21. Yin Cheng · 1 shared paper, 2014 · strength 0.04
  22. Jian Guan · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.